Xiaflex: Ph I started

BioSpecifics Technologies began an open-label, dose-escalation, sham-controlled, U.S. Phase I trial to evaluate single doses of 0.05, 0.1, 0.2 and 1.16 mg Xiaflex injected directly into the fibroid pr...